<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="954">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05148728</url>
  </required_header>
  <id_info>
    <org_study_id>PR(AG)401/2021</org_study_id>
    <nct_id>NCT05148728</nct_id>
  </id_info>
  <brief_title>Active Surveillance vs in Office Fulguration for Low Grade Bladder Cancer Tumors</brief_title>
  <official_title>Prospective Randomized Trial in Low Grade Bladder Tumors: Active Surveillance vs Endoscopic Fulguration.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vall Hebron Insitut Recerca</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vall Hebron Insitut Recerca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Biological behabiour of low grade bladder cancer tumors is well known. They have a very high&#xD;
      rate of recurrences during their follow up but very low (less than 1%) risk of progression.&#xD;
&#xD;
      Until now, the gold standard of any bladder recurrence for this patients is performing an&#xD;
      immediate transurethral ressection of the tumor.&#xD;
&#xD;
      This surgery has risk of complications and, due to the low risk of these subgroup of tumors,&#xD;
      sometimes it becomes an overtreatment for the patients.&#xD;
&#xD;
      This is the reason why new conservative or less invasive surgeries are proposed to follow up&#xD;
      and treat these patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2021</start_date>
  <completion_date type="Anticipated">March 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression rate</measure>
    <time_frame>two years</time_frame>
    <description>Number of patients that progress during the follow up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complications rate</measure>
    <time_frame>two years</time_frame>
    <description>Number and grade of complications in both arms. Clavien Dindo Scale will be used</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>recurrence rate</measure>
    <time_frame>two years</time_frame>
    <description>number of recurrences</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life measured with CAVICAVENMI questionnaire</measure>
    <time_frame>two years</time_frame>
    <description>quality of life of the patients in both subgroups. CAVICAVENMI questionnaire will be used</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Active surveillance</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>After a recurrence in patient with previous low grade bladder cancer tumor, strict follow up with cystoscopy and cytology, avoiding immediate surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>endoscopic fulguration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After a recurrence in patient with previous low grade bladder cancer tumor, fulguration under local anesthesia and sedation will be performed using a flexible cystoscope and a monopolar electrode</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic fulguration</intervention_name>
    <description>already included. WE will use Storz monopolar device for fulguration</description>
    <arm_group_label>endoscopic fulguration</arm_group_label>
    <other_name>Active surveillance</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Recurrent Ta-T1a (above muscularis mucosa) LOW GRADE bladder tumor&#xD;
&#xD;
          -  Accept cystoscopy surveillance&#xD;
&#xD;
          -  Main lession less than 10mm&#xD;
&#xD;
          -  Less than 7 lesions&#xD;
&#xD;
          -  Negative or low grade cytology&#xD;
&#xD;
          -  No solid aspect&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  previous High grade bladder cancer tumors&#xD;
&#xD;
          -  previous Cis&#xD;
&#xD;
          -  previous Upper Urinary Tract tumor&#xD;
&#xD;
          -  previous pelvic radiotherapy&#xD;
&#xD;
          -  hematuria&#xD;
&#xD;
          -  meatal localisation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fernando Lozano Palacio</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Fernando FL Lozano, MD</last_name>
      <phone>+34636244960</phone>
      <email>flozano@vhebron.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 26, 2021</study_first_submitted>
  <study_first_submitted_qc>December 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2021</study_first_posted>
  <last_update_submitted>December 7, 2021</last_update_submitted>
  <last_update_submitted_qc>December 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>active surveillance</keyword>
  <keyword>fulguration</keyword>
  <keyword>bladder cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>codified information (anonymous information)</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>after completing the recruitment (two years), data will be available, for 5 years</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

